← All trials
NCT06177431
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Apr 1, 2025
- Completion date
- Apr 1, 2025
- First posted
- Dec 20, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PharmAust LtdLead sponsor
- Macquarie UniversityCollaborator
- Macquarie UniversityOverall official - principal investigator
- Calvary Health Care BethlehemCollaborator
- Calvary Health Care BethlehemOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.